Vincent Rajkumar: Results of the CEPHEUS trial presented by Saad Z. Usmani at Myeloma Society meeting

Vincent Rajkumar shared a thread on X:

“Just out: Results of the CEPHEUS trial presented by Saad Z. Usmani and Memorial Sloan Kettering Cancer Center at the Plenary Session at Myeloma Society.

Significant improvement in PFS with Dara-VRd compared to VRd in patients who were transplant ineligible or deferred. Median age 70.

Here is the trial schema. Although they continued the triplet till progression, I’d recommend one year of quadruplet therapy followed by just Len alone for standard risk and the Dara plus Len reserved only for high risk, for now.

Significant difference in MRD negative rate with the quadruplet of Dara VRd.

This trial was done in the middle of COVID. There were more covid related deaths in quad arm. But OS attend favors Dara VRd.

CEPHEUS supports use of quads as initial therapy in transplant ineligible patients who are not frail, complementing data from the IMROZ trial which used Isatuximab-VRd.

Source: Vincent Rajkumar/X

Vincent Rajkumar is a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, and Chair for the Mayo Clinic Myeloma, Amyloidosis, and Dysproteinemia Group.  He also chairs the Board of directors of The International Myeloma Foundation and the Eastern Cooperative Oncology Group (ECOG) Myeloma Committee. His extensive contributions include over 230 peer-reviewed publications, predominantly focusing on multiple myeloma and related plasma cell disorders. Furthermore, Dr. Rajkumar is a Section Editor for multiple myeloma and related disorders for Leukemia and an Associate Editor for the Mayo Clinic Proceedings.